Introduction:
Viral infections undoubtedly constitute the biggest pandemic threat in
the modern era due to lack of ‘broad-spectrum’ antiviral agents.
Whereas, the threat is much less in case of bacteria in spite of their
more virulent natrure, due to development of multiple novel
antibacterial drugs.[1] The major concern in
antiviral drug development is to preserve the host cell function normal,
though the viruses utilise host cell machinery due to their obligate
parasite nature. Other obstacles are differences between RNA and DNA
viruses, vastly different virally encoded proteins across viral
families, single or double strand genomic structure and cytoplasmic or
nuclear replications cycles. Present approach remains aiming finding
treatments for specific individual viruses of concern rather than their
families. In most of the cases of novel viral epidemic, supportive care
remains the mainstay of therapy rather than antiviral drug. So,
development of novel broad spectrum antivirals is of utmost importance
in present time.